A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
=== Disease === Neon tetras are occasionally afflicted by the so-called "neon tetra disease" (NTD) or pleistophora disease, a sporozoan disease caused by Pleistophora hyphessobryconis. Despite being a well-known condition, it is generally incurable and often fatal to the fish. However this disease is also generally preventable. The disease cycle begins when microsporidian parasite spores enter the fish after it consumes infected material, such as the bodies of a dead fish, or live food such as tubifex, which may serve as intermediate hosts. The disease is most likely passed by newly acquired fish that have not been quarantined. Symptoms include restlessness, loss of coloration, lumps on the body as cysts develop, difficulty swimming, curved spines as the disease progresses, and secondary infections, such as fin rot and bloating. A so-called "false neon disease", which is bacterial, shows very similar symptoms. It is impossible for the home aquarist to determine for certain the difference between NTD and false NTD on the basis of visible symptoms alone, without laboratory backup. This disease has also been confused with columnaris (mouth rot, mouth fungus, 'flex'). Generally the best 'treatment' is the immediate removal of diseased fish to preserve the remaining fish, although some occasional successful treatments have been performed that include fish baths and a "medication cocktail". The use of a diatom filter, which can reduce the number of free parasites in the water, may help.
=== Further reading === The Eighth Day of Creation: Makers of the Revolution in Biology. Touchstone Books, ISBN 0-671-22540-5. 2nd edition: Cold Spring Harbor Laboratory Press, 1996 paperback: ISBN 0-87969-478-5. Micklas, David. 2003. DNA Science: A First Course. Cold Spring Harbor Press: ISBN 978-0-87969-636-8. Rasmussen, Nicolas, Gene Jockeys: Life Science and the rise of Biotech Enterprise, Johns Hopkins University Press, (Baltimore), 2014. ISBN 978-1-42141-340-2. Rosenfeld, Israel. 2010. DNA: A Graphic Guide to the Molecule that Shook the World. Columbia University Press: ISBN 978-0-231-14271-7. Schultz, Mark and Zander Cannon. 2009. The Stuff of Life: A Graphic Guide to Genetics and DNA. Hill and Wang: ISBN 0-8090-8947-5. Watson, James. 2004. DNA: The Secret of Life. Random House: ISBN 978-0-09-945184-6.
== History of discovery == Profilin was first described by Lars Carlsson in the lab of Uno Lindberg and co-workers in the early 1970s as the first actin monomer binding protein. It followed the realization that not only muscle, but also non-muscle cells, contained high concentrations of actin, albeit in part in an unpolymerized form. Profilin was then believed to sequester actin monomers (keep them in a pro-filamentous form), and release them upon a signal to make them accessible for fast actin polymer growth.
=== Biphasic half-life === Many drugs show a biphasic decline in plasma concentration after a dose: a steep distribution phase as drug leaves the central compartment for tissues (α phase), followed by a shallower elimination phase as drug is cleared (β phase). On a semi-log plot the two phases are approximately linear, with slopes α and β, and corresponding half-lives t1/2α = 0.693/α and t1/2β = 0.693/β. For single doses of lipophilic, multi-compartment drugs, clinical duration after onset is often driven by the distribution (α) phase, because by the time distribution equilibrium is reached plasma levels are frequently below any minimal effective concentration, so the terminal β phase has little bearing on observable effects. As a result, classifying drugs by terminal (β) half-life can poorly predict duration of action, whereas α half-life is often more informative—though less commonly reported in labels and reviews. Exceptions exist when elimination is extremely rapid: for very short-acting agents, the β phase can meaningfully shorten effect duration even after a single dose (e.g., triazolam, midazolam). The longer half-life is called the terminal half-life and the half-life of the largest component is called the dominant half-life. For a more detailed description see Pharmacokinetics § Multi-compartmental models.
Sources: en.wikipedia.org
AM-1235 metabolism differs only slightly from that of JWH-018. AM-1235 N-dealkylation produces 1-fluoropentane instead of pentane or other simple alkanes in general. It had been speculated that the fluoropentane might function as an alkylating agent or be further metabolized into toxic fluoroacetic acid. This is not true, however, as fluoroalkanes do not act as alkylating agents under normal conditions and odd-length fluoroalkane chains metabolize into substantially less toxic fluoropropanoic acid.
In osteology, the osteon or haversian system (; named for Clopton Havers) is the fundamental functional unit of much compact bone. Osteons are roughly cylindrical structures that are typically between 0.25 mm and 0.35 mm in diameter. Their length is often hard to define, but estimates vary from several millimeters to around 1 centimeter. They are present in many bones of most mammals and some bird, reptile, and amphibian species.
The leaves are unique among seed plants, being fan-shaped with veins radiating out into the leaf blade, sometimes bifurcating (splitting), but never anastomosing to form a network. Two veins enter the leaf blade at the base and fork repeatedly in two; this is known as dichotomous venation. The leaves are usually 5–10 cm (2–4 in), but sometimes up to 15 cm (6 in) long. The old common name, maidenhair tree, derives from the leaves resembling pinnae of the maidenhair fern, Adiantum capillus-veneris. Ginkgos are prized for their autumn foliage, which is a deep saffron yellow. The species is heterophyllous (two types of leaves); those on the long shoots are thicker, have higher rates of photosynthesis, higher vein density and leaf hydraulic conductance, while those on the short shoots are better at handling drought. Leaves of long shoots are also usually notched or lobed, but only from the outer surface, between the veins. They are borne both on the more rapidly growing branch tips, where they are alternate and spaced out, and also on the short, stubby spur shoots, where they are clustered at the tips. Leaves are green both on the top and bottom and have stomata on both sides. During autumn, the leaves turn a bright yellow and then fall, sometimes within a short space of time (one to fifteen days). Leaves of the cultivar 'Tubifolia' have funnel-shaped leaves.
Sources: en.wikipedia.org
Hyberbaric Oxygen Therapy Wound Debridement, a minor surgical procedure enhances the growth of healthy tissues in the wound Transcutaneous Oxygen Monitoring, a test that records the level of oxygen available to your wound Doppler Evaluation of Pulses, a technique that measures the blood flow available to bring nutrients and medications to the wound
==== Mixed oxidant ==== A simple brine {salt + water} solution in an electrolytic reaction produces a powerful mixed oxidant disinfectant (mostly chlorine in the form of hypochlorous acid (HOCl) and some peroxide, ozone, chlorine dioxide).
== Clinical Research and Clinical Trials == Clinical research at the Barshop Institute is dedicated to translating discoveries in the biology of aging into interventions that improve healthspan, preserve functional independence, and prevent or delay the onset of chronic age-related diseases. The Institute maintains a robust clinical research infrastructure that supports Phase I–IV clinical trials, investigator-initiated studies, and multicenter collaborations spanning basic translational research through large-scale clinical investigations. Investigators conduct studies involving older adults across a broad spectrum of aging-related conditions, including frailty, sarcopenia, metabolic dysfunction, obesity, type 2 diabetes, cardiovascular disease, Alzheimer's disease and related dementias, mobility impairment, osteoporosis, and other chronic conditions that disproportionately affect aging populations. Clinical trials evaluate novel therapeutics, lifestyle interventions, nutritional strategies, exercise programs, and repurposed medications designed to improve physical function, cognitive health, metabolic resilience, and overall quality of life. The Institute's clinical research enterprise is strengthened through close collaboration among physician-scientists, basic scientists, biostatisticians, epidemiologists, rehabilitation specialists, nutrition experts, and clinical research professionals.
== NAAS selected bibliography == 1955 Nuclear magnetic resonance saturation and rotary saturation in solids. Physical Review 98(6):1787–1809. 1959 With A. G. Anderson. Nuclear spin-lattice relaxation in metals. Physical Review 116(3):583–591. 1963. Pure nuclear electric quadrupole resonance in impure copper. Physical Review 130(2):589–595. 1963 With M. Eisenstadt. Nuclear spin relaxation by translational diffusion in solids. Physical Review 132(2):635–643. Pure nuclear electric quadrupole resonance in impure copper. Physical Review 130(2):589–595. 1965 The theory of relaxation processes. In Advances in Magnetic and Optical Resonance, pp. 1–32. 1967 Local-field mapping in mixed-state superconducting vanadium by nuclear magnetic resonance. Physical Review 162(2):367–374. 1969 Nuclear spin thermodynamics in the rotating frame. Science 164(3883):1015–1023. 1970 With R. K. Gupta. Double nuclear magnetic resonance observation of electron exchange between ferri- and ferrocytochrome c. Science 169(3951):1204–1206. 1971 With H. E. Bleich. Higher resolution NMR of rare spins in solids [1]. The Journal of Chemical Physics 55(11):5405–5406. 1971 With R. K. Gupta. Pulsed Fourier transform nuclear magnetic resonance spectrometer. In Advances in Magnetic and Optical Resonance, pp. 81–115. 1973 With A. Z. Genack. Nuclear spin diffusion and its thermodynamic quenching in the field gradients of a Type-II superconductor. Physical Review Letters 31(19):1204–1207. 1975 With S. D. Kunz and E. K. Ralph. Dynamic range in Fourier transform proton magnetic resonance.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.